GMP Manufacturing and Characterization of the HIV Booster Immunogen HxB2.WT.Core-C4b for Germline Targeting Vaccine Strategies
This work establishes a robust, scalable platform for HIV nanoparticle immunogens. Consistent quality and yield across scales support clinical development of HxB2.WT.Core-C4b and provide a model for other glycosylated nanoparticle vaccines. The immunogen is being evaluated in clinical study HVTN 320 (NCT06796686), enabling early testing of next-generation vaccines designed to elicit broadly neutralizing antibodies.
Authors
- Leonidas Stamatatos (ORCID: https://orcid.org/0000-0002-1106-7097)
- Dietmar Katinger (ORCID: https://orcid.org/0000-0002-0536-3148)
- Mingchao Shen (ORCID: https://orcid.org/0000-0001-9714-8076)
- Latha Kallur Siddaramaiah
- John R. Yates (ORCID: https://orcid.org/0000-0001-5267-1672)
- James C. Paulson (ORCID: https://orcid.org/0000-0003-4589-5322)
- Gabriel Ozorowski (ORCID: https://orcid.org/0000-0002-9695-8138)
- D.Baxter Craig
- Ryan Swoyer
- Srinivas Reddy Pallerla (ORCID: https://orcid.org/0000-0003-1669-1515)
- Katharina Fauland
- Philipp Mundsperger (ORCID: https://orcid.org/0000-0002-9095-5657)
- Maoli Yuan (ORCID: https://orcid.org/0000-0002-1395-5418)
- Önder Arslan (ORCID: https://orcid.org/0000-0002-6164-4059)
- Robert Weik
- Wen-Hsin Lee
- Tracy Blumen
- Günter Kreismayr
Institutions
- Scripps Research Institute (US)
- International AIDS Vaccine Initiative (US)
- Fred Hutch Cancer Center (US)
- Polymun (Austria) (AT)
Publication Details
- Journal
- Vaccines
- Published
- 2025-09-18
- DOI
- https://doi.org/10.3390/vaccines13090980
- Primary Topic
- HIV Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Health and Human Services
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases